EA200801447A1 - Фармацевтическая композиция - Google Patents

Фармацевтическая композиция

Info

Publication number
EA200801447A1
EA200801447A1 EA200801447A EA200801447A EA200801447A1 EA 200801447 A1 EA200801447 A1 EA 200801447A1 EA 200801447 A EA200801447 A EA 200801447A EA 200801447 A EA200801447 A EA 200801447A EA 200801447 A1 EA200801447 A1 EA 200801447A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
products
hept
methylsulfonyl
pyrimidin
Prior art date
Application number
EA200801447A
Other languages
English (en)
Other versions
EA015682B1 (ru
Inventor
Миха Томаз Яклиц
Клемен Наверсник
Original Assignee
Лек Фармасьютиклз Д.Д.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лек Фармасьютиклз Д.Д. filed Critical Лек Фармасьютиклз Д.Д.
Publication of EA200801447A1 publication Critical patent/EA200801447A1/ru
Publication of EA015682B1 publication Critical patent/EA015682B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Химически стабильная композиция (Е)-7-[4-(4-фторфенил)-6-изопропил-2-[метил(метилсульфонил)амино]пиримидин-5-ил]-(3R, 5S)-3,5-дигидрокси-гепт-6-еновой кислоты или ее фармацевтически приемлемой соли для перорального применения, такая как таблетки, капсулы, порошки, гранулы, была разработана с использованием стабилизирующих веществ, препятствующих образованию продуктов распада: лактона и продуктов окисления.
EA200801447A 2005-12-20 2006-12-18 Фармацевтическая композиция EA015682B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200500344 2005-12-20
PCT/EP2006/012180 WO2007071357A2 (en) 2005-12-20 2006-12-18 Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid

Publications (2)

Publication Number Publication Date
EA200801447A1 true EA200801447A1 (ru) 2008-12-30
EA015682B1 EA015682B1 (ru) 2011-10-31

Family

ID=37866173

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801447A EA015682B1 (ru) 2005-12-20 2006-12-18 Фармацевтическая композиция

Country Status (9)

Country Link
US (1) US20090093499A1 (ru)
EP (1) EP1968593B1 (ru)
JP (1) JP5235676B2 (ru)
CN (1) CN101330919B (ru)
AU (1) AU2006329006B2 (ru)
BR (1) BRPI0620629B8 (ru)
CA (1) CA2630704C (ru)
EA (1) EA015682B1 (ru)
WO (1) WO2007071357A2 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994178B2 (en) 2006-09-18 2011-08-09 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin calcium and compositions thereof for treatment of hyperlipidaemia
EP2285353A1 (en) * 2008-01-30 2011-02-23 Lupin Limited Modified release formulations of hmg coa reductase inhibitors
EP2309992B1 (en) * 2008-06-27 2017-10-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
TR200902077A2 (tr) 2009-03-17 2010-01-21 Sanovel İlaç San.Veti̇c.A.Ş. Stabil rosuvastatin kompozisyonları
RU2606592C1 (ru) * 2015-10-07 2017-01-10 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция, содержащая кальциевую соль розувастатина (варианты)
CA3166050C (en) * 2019-12-31 2024-02-20 Pfizer R&D Uk Limited Stable immediate release tablet and capsule formulations of 1-((2s,5r)-5-((7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB0000710D0 (en) * 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US6399101B1 (en) * 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
CA2440588C (en) * 2001-03-13 2010-02-09 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
SE0101329D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Pharmaceutical formulation
GB0111077D0 (en) * 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
WO2003080023A2 (en) * 2002-03-20 2003-10-02 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
WO2003090723A1 (en) * 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
AU2003227691B2 (en) * 2002-05-03 2008-05-15 Hexal Ag Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
WO2005040134A1 (en) * 2003-10-22 2005-05-06 Ranbaxy Laboratories Limited Process for the preparation of amorphous rosuvastatin calcium
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
ES2364143T3 (es) * 2003-12-02 2011-08-25 Teva Pharmaceutical Industries Ltd. Estandar de referencia para caracterización de rosuvastatina.
WO2005077917A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Amorphous salts of rosuvastatin
EP1709008A1 (en) * 2004-01-19 2006-10-11 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof

Also Published As

Publication number Publication date
AU2006329006A1 (en) 2007-06-28
AU2006329006B2 (en) 2013-02-28
BRPI0620629B8 (pt) 2021-05-25
BRPI0620629B1 (pt) 2020-01-14
EP1968593B1 (en) 2017-08-23
EP1968593A2 (en) 2008-09-17
JP2009519985A (ja) 2009-05-21
WO2007071357A2 (en) 2007-06-28
BRPI0620629A2 (pt) 2011-11-16
CN101330919A (zh) 2008-12-24
EA015682B1 (ru) 2011-10-31
CN101330919B (zh) 2012-12-05
CA2630704A1 (en) 2007-06-28
JP5235676B2 (ja) 2013-07-10
CA2630704C (en) 2014-08-19
US20090093499A1 (en) 2009-04-09
WO2007071357A3 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
EA200801447A1 (ru) Фармацевтическая композиция
MY122707A (en) Pharmaceutical compositions
CY1110992T1 (el) ΣΥΝΔΥΑΣΜΕΝΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΠΕΡΙΕΧΟΥΝ (Ε)-7-[4-(4-ΦΘΟΡΟΦΑΙΝΥΛ)-6-ΙΣΟΠΡΟΠΥΛ-2-[ΜΕΘΥΛ(ΜΕΘΥΛΣΟΥΛΦΟΝΥΛ)ΑΜΙΝΟ]ΠΥΡΙΜΙΔΙΝ-5-ΥΛ](3r,5s)-3,5-ΔΙΥΔΡΟΞΥΕΠΤ-6-ΕΝΟΪΚΟ ΟΞΥ
CY1109756T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν κρυσταλλικα αλατα 7-[4-(4-φθοροφαινυλ)-6-ισοπροπυλ-2- [μεθυλ(μεθυλσουλφονυλ)αμινο] πυριμιδιν-5-υλ]-(3r,5s)-3,5-διυδροξυεπτ-6-ενοϊκου οξεος
TWI370817B (en) Novel crystalline form of bis[(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[ methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt,and relevant manufacture process, pharmaceutical composition, and use
IL155919A (en) (e) - 7 - [4 - (4 - fluorophenyl) - 6 - isopropyl - 2 - [methyl ( methylsulfonyl) amino] pyrimidin - 5 - yl] (3r, 5s) - dihydroxyhept - 6 - enoic acid, or a pharmaceutically acceptable salt thereof, for use as a medicament for the treatment of heterozygous familial hypercholesterolemia
EA201100032A1 (ru) Соединения пиридина
EA200971069A1 (ru) Метаболиты производных (тио)карбомоилциклогексана
RS51923B (en) SO 4 [[4 - [[4- (2-CYANOETHENYL) -2,6-DIMETHYLPHENYL] AMINO] -2-PYRIMIDINYL] AMINO] BENZONITRILA
JP2007277267A5 (ru)
EA200701923A1 (ru) Лекарственная форма для перорального введения витамина
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
TW200744583A (en) Statin stabilizing dosage formulations
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
WO2010030201A3 (en) Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid
AR022462A1 (es) Uso de un agente que disminuye el colesterol
TW201129557A (en) Pharmaceutical composition for oral administration
JP6750785B2 (ja) 安定なロスバスタチンカルシウム錠剤
BRPI0514861A (pt) furamato de 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidi nil)amino)benzonitrila
JP6573098B2 (ja) 安定なロスバスタチンカルシウム錠剤
UY30336A1 (es) Composiciones farmacéuticas conteniendo ácido (e)-7-(4-(4-fluorofenil)-6-isopropil-2-(metil(metilsulfonil)amino)pirimidin-5-il)-(3r,5s)-3,5-dihidroxihept-6-enoico y sales farmacéuticamente aceptables de la misma
TR200800269A2 (tr) Stabil farmasötik formülasyon ve hazırlama yöntemleri
TH88724A (th) การรักษา
HRP20110563T1 (en) Salt of 4[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
TH88724B (th) การรักษา

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM